Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ProMetic Life Sciences has received confirmation for the approval of OctaplasLG for additional European Union (EU) countries, from Octapharma.
Subscribe to our email newsletter
The approval has been confirmed for the UK, Belgium, Finland, Ireland, Luxemburg, Netherlands and Sweden.
Octapharma’s manufacturing process for OctaplasLG, which is a solvent/detergent treated, prion-reduced, plasma product is incorporated with prion capture resin, PrioClear by ProMetic.
ProMetic has secured a purchase order and binding forecast from Octapharma for around $3m of PrioClear resin to be manufactured between December 2011 and June 2012.
ProMetic Life Sciences CEO Pierre Laurin said these countries are major markets for their growth along with Octapharma.
"We expect other key markets to adopt and follow the industry’s migration towards safer plasma derived products and we are pleased with Octpharma’s plan to advance OctaplassLG in North America," Laurin added.